En bloc resection

整体切除术
  • 文章类型: Journal Article
    背景:水下内镜下黏膜切除术(uEMR)代表了传统EMR的替代方法,用于切除无柄结直肠息肉。我们旨在评估uEMR治疗无柄结直肠息肉的疗效和安全性。
    方法:对2021年1月至2023年6月期间印度西部两个三级护理中心接受uEMR治疗10mm以上无任何粘膜下浸润特征的无蒂结直肠息肉患者的内镜数据库进行了回顾性分析。排除标准是其他内窥镜切除模式。主要结果是整块切除术率。次要结果是完全切除率,不良事件和复发率。
    结果:在研究期间,159例261个病变患者符合研究纳入。平均病灶大小为1.935±0.71cm,大部分病灶位于直肠(75,28.73%),其次是乙状结肠(69,26.43%)。大多数病变具有巴黎0-Is形态(192,73.56%)。日本NBI专家组(JNET)IIa模式在窄带成像(NBI)中观察到221(84.67%)个病变。98.46%的病变完全切除(257/261)。91.82%(236/257)的病灶整体切除。并发症发生率为6.8%,所有这些都是通过内窥镜管理的。随访发现3.1%的息肉复发。
    结论:uEMR是一种安全有效的内镜下切除无蒂结直肠息肉的技术,对于大于10mm的息肉,整块切除率很高。
    BACKGROUND: Underwater endoscopic mucosal resection (uEMR) represents an alternative to conventional EMR for resection of sessile colorectal polyps. We aimed at assessing the efficacy and safety of uEMR for sessile colorectal polyps.
    METHODS: A retrospective analysis of endoscopy database was done for patients who underwent uEMR for sessile colorectal polyps more than 10 mm in size without any features of sub-mucosal invasion from two tertiary care centres in western India between January 2021 and June 2023. Exclusion criteria were other modes of endoscopic resection. Primary outcome was rate of en bloc resection. Secondary outcomes were complete resection rate, adverse events and recurrence rate.
    RESULTS: During the study period, 159 patients with 261 lesions met the study inclusion. Mean lesion size was 1.935 ± 0.71 cm with most lesion located in the rectum (75, 28.73%) followed by sigmoid colon (69, 26.43%). Most lesions had a Paris 0-Is morphology (192, 73.56%). Japan NBI Expert Team (JNET) IIa pattern was seen on narrow band imaging (NBI) in 221 (84.67%) lesions. Complete resection was achieved in 98.46% lesions (257/261). En bloc resection was achieved in 91.82% (236/257) lesions. Complications were seen in 6.8%, all of which were managed endoscopically. Recurrence was seen in 3.1% of polyps on follow-up.
    CONCLUSIONS: uEMR is a safe and efficacious technique for endoscopic resection for sessile colorectal polyps with high rates of en bloc resection for polyps more than 10 mm size.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:我们为可切除的非小细胞肺癌(NSCLC)建立了一种新的手术方法,其中包括切除受影响的肺叶和区域淋巴结而不分离,即整体手术。我们通过与常规手术进行比较,介绍了技术细节以及早期和晚期结果。
    方法:我们回顾性分析I-III期非小细胞肺癌行肺叶切除、肺门和纵隔淋巴结清扫术的患者。基于人口统计学变量进行倾向得分匹配分析。
    结果:倾向得分匹配产生317对。整体手术与更长的手术时间无关,术中出血量较多,或术后并发症的频率更高。两组之间的淋巴结切除数(P=0.277)和N分期频率(P=0.587)没有差异。然而,与传统手术相比,整体手术的总生存率更高(P=0.012).根据分层分析,在病理性N阳性疾病中,整块手术相对于传统手术的生存优势显着(P=0.005),而在病理性N阴性疾病中消失(P=0.147)。
    结论:En整块手术是可行的,可以在N阳性NSCLC患者中进行。
    OBJECTIVE: We established a novel surgical procedure for resectable non-small-cell lung cancer (NSCLC), which involves resection of the affected lobe and regional lymph nodes without separation, namely en bloc surgery. We introduced the technical details and early and late outcomes by comparing them with those of conventional surgery.
    METHODS: We retrospectively analyzed patients who underwent lobectomy with hilar and mediastinal lymph node dissection for stages I-III NSCLC. A propensity score-matched analysis was performed based on demographic variables.
    RESULTS: Propensity score-matching yielded 317 pairs. En bloc surgery was not associated with a longer operation time, a higher amount of intraoperative bleeding, or a higher frequency of postoperative complications. The number of resected lymph nodes (P = 0.277) and frequency of N upstaging (P = 0.587) did not differ between the groups. However, en bloc surgery was associated with higher overall survival in comparison to conventional surgery (P = 0.012). According to a stratification analysis, the survival advantage of en bloc surgery over conventional surgery was remarkable in pathological N-positive disease (P = 0.005), whereas it disappeared in pathological N-negative disease (P = 0.147).
    CONCLUSIONS: En bloc surgery is feasible and can be performed in patients with possible N-positive NSCLC.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    背景:肾上腺皮质癌(ACC)是一种罕见且侵袭性的内分泌恶性肿瘤,复发率高。大约一半的患者无症状,而其他人则由于肿瘤的大小或激素分泌而出现症状。如果可能,Ro切除是治疗原发性和局部复发性ACC的最佳选择。
    方法:一名20岁女性曾接受过III期ACC的左肾上腺开放性切除术,主诉左上腹部有沉重和模糊的不适。目前的激素测定是正常的。影像学显示脾脏有病变,提示复发。她接受了选择性手术,包括脾脏整块切除术,隔膜,和相关的结构。术后恢复顺利,组织病理学证实复发,随后的PET-CT显示无复发.她目前正在服用米托坦,并且在初次手术后仍然没有症状,没有复发的迹象。
    如果可能,完全切除(Ro),复发和转移性疾病与长期生存有关,并提供显著的姑息治疗益处,特别是在涉及有症状的类固醇产生的病例中。
    结论:ACC局部复发的频率很高,因此从最初诊断开始就应考虑复发的处理。Ro切除复发是最好的潜在治疗方法。后续协议和改善手术之间的整合,肿瘤学,和支持性护理部门对于克服尼泊尔的医疗保健挑战至关重要。
    BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy with a high recurrence rate. Approximately half of the patients are asymptomatic, while others experience symptoms due to the tumor\'s size or hormone secretion. Ro resection if possible is the best option for treatment of primary as well as locoregional recurrent ACC.
    METHODS: A 20-year-old female who previously underwent open left adrenalectomy for Stage III ACC presented with complaints of heaviness and vague discomfort in the left upper abdomen. Current hormonal assays were normal. Imaging revealed a lesion in the spleen suggestive of recurrence. She underwent elective surgery involving en bloc resection of the spleen, diaphragm, and associated structures. Postoperative recovery was uneventful, histopathology confirmed recurrence and subsequent PET-CT showed no recurrence. She is currently on mitotane and remains symptom-free with no signs of recurrence after initial surgery.
    UNASSIGNED: Complete resection (Ro) if possible, for recurrent and metastatic disease has been linked to long-term survival and offers significant palliative benefits, particularly in cases involving symptomatic steroid production.
    CONCLUSIONS: ACC has a high frequency of local recurrence therefore management of recurrence should be considered from the initial diagnosis. Ro resection of recurrence is the best potential treatment. Follow-up protocols and improving integration between surgical, oncological, and supportive care departments are crucial for overcoming healthcare challenges in Nepal.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    需要整块切除术来治疗具有骨外延伸的中级距骨肿瘤(Enneking3期)和没有关节内侵袭的恶性距骨肿瘤(EnnekingIA和IIA期)。切除后,重建方案包括胫骨骨融合,冷冻自体移植物,和距骨假体;然而,距骨假体是优选的,因为它保留了踝关节的活动范围,不会导致腿部长度差异,并与良好的长期结果有关。据我们所知,先前尚未详细报道恶性距骨肿瘤的整块切除和重建。我们报告了一种详细的手术技术,该技术使用前后路联合方法对恶性距骨骨肿瘤进行整块切除,然后使用距骨假体进行重建。
    En bloc resection is required for treatment of intermediate-grade talar tumors with extraosseous extension (Enneking stage 3) and malignant talar tumors without intra-articular invasion (Enneking stages IA and IIA). After resection, reconstruction options include tibiocalcaneal fusion, frozen autograft, and talar prosthesis; however, a talar prosthesis is preferable because it preserves ankle range of motion, does not cause leg length discrepancy, and is associated with good long-term outcomes. To the best of our knowledge, en bloc resection and reconstruction of a malignant talar tumor has not been previously reported in detail. We report a detailed surgical technique for en bloc resection of a malignant talar bone tumor using combined anterior and lateral approaches followed by reconstruction using a talar prosthesis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:在诊断为T1高级别(T1HG)膀胱癌后,建议再次进行经尿道膀胱切除术(re-TUR)。很少有研究评估首次整块切除术(EBR)后的re-TUR结果,并且没有一项研究具体报道了先前T1疾病领域的病理结果。
    目的:报告EBR切除的T1HG病灶的上分期率和残留病率(RD)。
    方法:在2014年1月至2022年6月之间,回顾性纳入了来自2个中心的患者,这些患者在T1HG尿路上皮癌行EBR后再次TUR。主要终点是RD的比率,包括在初次切除的疤痕上升级到T2疾病的比率。次要终点是场外任何残留疾病的发生率。
    结果:纳入75例患者。重新TUR后未发现肌层浸润性膀胱癌病变。在16名患有RD的患者中,4在切除疤痕上。所有这些病变均为乳头状和高级别。在12例患者中观察到第一个EBR视野外的RD。
    结论:T1HG病EBR后,我们的病人都没有向MIBC升级.然而,EBR场内外的RD率仍然相当显著。我们建议残留乳头状疾病的预测因素(初始TUR和伴随的CIS处的肿瘤数量)可能适合选择将受益于重新TUR的患者。
    BACKGROUND: A second look trans-urethral resection of the bladder (re-TUR) is recommended after the diagnosis of T1 high grade (T1HG) bladder cancer. Few studies have evaluated the results of re-TUR after a first en bloc resection (EBR) and none of them have specifically reported the pathological results on the field of previous T1 disease.
    OBJECTIVE: To report the rate of upstaging and the rate of residual disease (RD) on the field of T1HG lesions resected with EBR.
    METHODS: Between 01/2014 and 06/2022, patients from 2 centers who had a re-TUR after an EBR for T1HG urothelial carcinoma were retrospectively included. Primary endpoint was the rate of RD including the rate of upstaging to T2 disease on the scar of the primary resection. Secondary endpoints were the rate of any residual disease outside the field.
    RESULTS: Seventy-five patients were included. No muscle invasive bladder cancer lesions were found after re-TUR. Among the 16 patients who had a RD, 4 were on the resection scar. All of these lesions were papillary and high grade. RD outside the field of the first EBR was observed in 12 patients.
    CONCLUSIONS: After EBR of T1HG disease, none of our patients had an upstaging to MIBC. However, the rate of RD either on and outside the field of the EBR remains quite significant. We suggested that predictive factors of residual papillary disease (number of tumors at the initial TUR and concomitant CIS) might be suitable to select patient who will benefit of the re-TUR.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    上皮样血管瘤被世界卫生组织认为是一种独特的良性肿瘤;然而,它的特点是局部侵袭性和很少转移行为。上皮样血管肿瘤是罕见的骨性血管病变,具有不同程度的恶性潜能,因其罕见而仍存在争议,不寻常的形态特征,和不可预测的生物学行为。新分子工具的应用,如大规模平行测序技术,提供了新的诊断标记物,并为进一步完善骨血管肿瘤的分类提供了机会。文献中很少报道脊柱EH的病例;因此,这些患者很难做出循证治疗决策.我们在此报告了11名患有脊柱EH的患者的经验。研究人群包括2016年至今在我们中心接受治疗的三名男性和八名女性;平均年龄为44.8岁(范围为14-75岁)。手术,临床,和影像学资料进行回顾性分析.平均随访34.8个月。所有患者均出现溶解性椎体病变,其中6例病理性骨折.大多数患者(80%)出现骨髓神经根压迫。所有患者均接受手术治疗,所有病例均进行术前栓塞。根据我们中心的文献综述和临床经验,我们可以认为EH是一种局部侵袭性肿瘤,在出现症状时需要手术治疗。这里,我们提出了一种治疗算法,该算法可用于治疗这种罕见疾病的患者。
    Epithelioid hemangioma is recognized by the World Health Organization as a distinct benign neoplasm; however, it is characterized by locally aggressive and rarely metastasizing behavior. Epithelioid vascular tumors are rare bony vascular lesions with varying degrees of malignant potential that remain controversial because of their rarity, unusual morphological features, and unpredictable biological behavior. The application of new molecular tools, such as massive parallel sequencing technologies, have provided new diagnostic markers and an opportunity to further refine the classification of bone vascular neoplasms. Very few cases of EH of the spine have been reported in the literature; therefore, it is difficult to make evidence-based therapeutic decisions for these patients. We report herein our experience with eleven patients suffering from EH of the spine. The study population included three males and eight females treated in our center from 2016 to the present; the average age was 44.8 years (range 14-75 years). The surgical, clinical, and radiographic data were retrospectively analyzed. The mean follow-up was 34.8 months. All patients presented lytic vertebral body lesions, six of them with pathological fracture. The majority of patients (80%) presented myelo-radicular compression. All patients were surgically treated, and preoperative embolization was performed in all cases. In light of the literature review and the clinical experience of our center, we can consider EH a locally aggressive tumor that requires surgical treatment in case of symptoms. Here, we propose a treatment algorithm that could be useful in the management of patients with this rare disease.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    Adamantinmas罕见,低档,恶性骨肿瘤仅占原发性恶性骨肿瘤的0.33-0.48%。
    方法:一名11岁的尺骨金刚砂男孩接受整块切除术治疗,氪石骨水泥,和钢板固定。手术导致明显的疼痛缓解和良好的功能恢复。术后5年无复发迹象,肌肉骨骼肿瘤学会得分为93分。
    这个11岁的患者曾接受过动脉瘤样骨囊肿(ABC)治疗,说明了诊断金刚烷虫瘤的复杂性,尤其是尺骨等非典型部位.整体切除和合成骨移植的成功使用凸显了准确诊断和先进手术方法在小儿骨科肿瘤学中取得良好结果的重要性。
    结论:尺骨adamantinoma罕见且难以诊断。这种肿瘤的成功治疗,正如这个案例报告中所描述的,可以帮助指导今后类似案件的管理。
    UNASSIGNED: Adamantinomas are rare, low-grade, malignant skeletal tumors accounting for only 0.33-0.48 % of primary malignant bone tumors.
    METHODS: An 11-year-old boy with adamantinoma of the ulna was treated with en bloc resection, kryptonite bone cement, and plate fixation. The surgery resulted in marked pain relief and good functional recovery. No evidence of recurrence was observed for 5 years postoperatively, and the Musculoskeletal Tumor Society score was 93.
    UNASSIGNED: This case of an 11-year-old previously treated for an aneurysmal bone cyst (ABC) illustrates the complexity of diagnosing adamantinoma, especially in atypical locations like the ulna. The successful use of en bloc resection and synthetic bone graft highlights the importance of accurate diagnosis and advanced surgical methods in achieving favorable outcomes in pediatric orthopedic oncology.
    CONCLUSIONS: Ulnar adamantinomas are rare and can be difficult to diagnose. The successful treatment of this tumor, as described in this case report, can help guide the management of similar cases in the future.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:内镜粘膜下剥离术(ESD)是一种技术上具有挑战性的切除技术,用于整块切除发育不良和早期癌性胃肠道(GI)病变。我们进行了一项单臂回顾性研究,评估了在6个美国学术中心进行的用于上下ESD手术的新型可穿针注射电外科刀的安全性和有效性。
    方法:回顾性收集使用新型ESD刀的连续病例资料。主要疗效终点是成功的ESD(整块切除,切缘阴性)。次要疗效终点包括整块切除率,治愈性切除率,ESD时间中位数,和中位数解剖速度。安全性终点是设备或程序相关的严重不良事件(SAE)。
    结果:评估了579例患者的581个病灶的ESD,包括187例(32.2%)上消化道和394例(67.8%)下消化道病变。在283例(48.9%)患者中报告了先前的治疗。成功的ESD在477个(581个中的82.1%)病变中实现,与没有粘膜下纤维化的患者相比,较低(73.6%对87.0%,分别,P<0.001),但与没有以前治疗的患者相似(81.7%对82.3%,分别,P=0.848)。443个(581个中的76.2%)病变符合根治性切除标准。ESD时间的中值为1.0(范围0.1-4.5)小时。平均解剖速度为17.1(IQR5.3-29.8)cm2/小时。15例(2.6%)患者报告了相关的SAE,包括延迟出血(1.9%),穿孔(0.5%),或息肉切除术后综合征(0.2%)。
    结论:一种新开发的可穿针注射的ESD刀在美国中心显示出良好的成功率和良好的安全性。(ClinicalTrials.gov编号,NCT04580940)。
    OBJECTIVE: Endoscopic submucosal dissection (ESD) is a technically challenging resection technique for en bloc removal of dysplastic and early cancerous GI lesions. We conducted a single-arm retrospective study evaluating the safety and efficacy of a new through-the-needle injection-capable electrosurgical knife used in upper and lower ESD procedures performed at 6 U.S. academic centers.
    METHODS: Data were retrospectively collected on consecutive cases in which the new ESD knife was used. The primary efficacy endpoint was successful ESD (en bloc resection with negative margins). Secondary efficacy endpoints included en bloc resection rate, curative resection rate, median ESD time, and median dissection speed. The safety endpoint was device- or procedure-related serious adverse events.
    RESULTS: ESD procedures of 581 lesions in 579 patients were reviewed, including 187 (32.2%) upper GI and 394 (67.8%) lower GI lesions. Prior treatment was reported in 283 (48.9%) patients. Successful ESD was achieved in 477 (82.1% of 581) lesions-lower for patients with versus without submucosal fibrosis (73.6% vs 87.0%, respectively; P < .001) but similar for those with versus without previous treatment (81.7% vs 82.3%, respectively; P = .848). A total of 443 (76.2% of 581) lesions met criteria for curative resection. Median ESD time was 1.0 (range, 0.1-4.5) hour. Median dissection speed was 17.1 (interquartile range, 5.3-29.8) cm2/h. Related serious adverse events were reported in 15 (2.6%) patients, including delayed hemorrhage (1.9%), perforation (0.5%), or postpolypectomy syndrome (0.2%).
    CONCLUSIONS: A newly developed through-the-needle injection-capable ESD knife showed a good success rate and excellent safety at U.S.
    METHODS: (Clinical trial registration number: NCT04580940.).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:评价胸腰椎肿瘤整块切除和前柱重建术的围手术期临床疗效。
    方法:本研究对86例连续患者的前瞻性数据收集进行了回顾性分析,包括40名男性和46名女性,平均年龄为39岁(10至71岁)。原发性恶性肿瘤35例,42例侵袭性良性肿瘤,和9例转移。病灶主要位于胸椎65例,腰椎17例,胸腰椎4例。45名患者的肿瘤涉及一个级别,12名患者的两个水平,21名患者的三个级别,五个病人的四个级别,两名患者的五个级别,一个病人有六个级别。
    结果:根据Weinstein-Boriani-Biagini手术分期系统,所有患者都实现了整体切除,其中全脊椎整块切除74例,矢状面切除12例。平均手术时间为559分钟(210-1208分钟),平均总失血量为1528ml(260-5500ml)。62例(72.1%)患者共观察到122例并发症,其中18例(20.9%)患者出现25种主要并发症,1例(1.2%)患者死于并发症。组合方法(P=0.002),总失血量(P=0.003),分期手术(P=0.004),既往手术史(P=0.045),受累椎体数量(P=0.021)和腰椎位置(P=0.012)是主要并发症的显著危险因素。当上述所有危险因素纳入多变量分析时,只有联合治疗(P=0.052)仍然显著.
    结论:整块切除和前柱重建术伴随着较高的并发症发生率,特别是当一个联合的方法是必要的。
    OBJECTIVE: To evaluate the perioperative clinical outcomes of en bloc resection and anterior column reconstruction for thoracolumbar spinal tumors.
    METHODS: This study conducted a retrospective analysis of prospective data collection of 86 consecutive patients, including 40 males and 46 females, with an average age of 39 years (ranged from 10 to 71 years). There were 35 cases of a malignant primary tumor,42 cases of an aggressive benign tumor, and nine cases of metastases. The main lesions were located in 65 cases of thoracic spine, 17 cases of lumbar spine, and 4 cases of thoracolumbar spine. Tumors involved one level in 45 patients, two levels in 12 patients, three levels in 21 patients, four levels in five patients, five levels in two patients, and six levels in one patient.
    RESULTS: According to the Weinstein-Boriani-Biagini surgical staging system, all patients achieved en bloc resections, including 74 cases of total en bloc spondylectomy and 12 cases of sagittal resections. The mean surgical time was 559 min (210-1208 min), and the mean total blood loss was 1528 ml (260-5500 ml). A total of 122 complications were observed in 62(72.1%) patients, of which 18(20.9%) patients had 25 major complications and one patient (1.2%) died of complications. The combined approach (P = 0.002), total blood loss (P = 0.003), staged surgery (P = 0.004), previous surgical history (P = 0.045), the number of involved vertebrae (P = 0.021) and lumbar location (P = 0.012) were statistically significant risk factors for major complication. When all above risk factors were incorporated in multivariate analysis, only the combined approach (P = 0.052) still remained significant.
    CONCLUSIONS: En bloc resection and anterior column reconstruction is accompanied by a high incidence of complications, especially when a combined approach is necessary.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:通常,标准切除术(SR)是通过以零碎的方式切除膀胱肿瘤来进行的。已提出膀胱肿瘤整块切除术(ERBT)作为治疗非肌肉浸润性膀胱癌(NMIBC)的替代技术。
    目的:探讨ERBT能否改善NMIBC的1年复发率,与SR相比。
    方法:多中心,随机化,3期试验在香港进行.从2017年4月至2020年12月纳入膀胱肿瘤≤3cm的成年人,并随访至手术后1年。
    方法:患者被随机分配接受1:1比例的ERBT或SR。
    方法:主要结果是1年复发率。对组织学证实为NMIBC的患者进行了改良的意向治疗分析。主要次要结果包括逼尿肌采样率,手术时间,住院,30d并发症,经尿道二次电切术后任何残留或升级的疾病,和1年进展率。
    结论:共有350名患者接受了随机分组,276例患者经组织学证实患有NMIBC。在1年,ERBT组31例,SR组46例复发;Kaplan-Meier估计的1年复发率为29%(95%置信区间,18-37)在ERBT组中,38%(95%置信区间,28-46)在SR组中(p=0.007)。根据亚组分析,1-3厘米肿瘤患者,单个肿瘤,Ta病,或中等风险的NMIBC从ERBT中获益显著.ERBT组的患者和SR组中的三名患者均未发展为肌肉浸润性膀胱癌;ERBT组的Kaplan-Meier估计的1年进展率分别为0%和2.6%(95%置信区间,0-5.5)在SR组(p=0.065)。中位手术时间为28分钟(四分位距,20-45)在ERBT组中和22分钟(四分位数间距,15-30)在SR组中(p<0.001)。两组的其他次要结局相似。
    结论:在NMIBC≤3cm的患者中,与SR(由GRF/ECS资助,RGC,参考编号:24116518;ClinicalTrials.gov编号,NCT02993211)。
    结果:按惯例,非肌肉浸润性膀胱癌是通过局部切除膀胱肿瘤来治疗的。在这项研究中,我们发现整块切除,也就是说,一块切除膀胱肿瘤,可以降低非肌层浸润性膀胱癌的1年复发率。
    OBJECTIVE: Conventionally, standard resection (SR) is performed by resecting the bladder tumour in a piecemeal manner. En bloc resection of the bladder tumour (ERBT) has been proposed as an alternative technique in treating non-muscle-invasive bladder cancer (NMIBC). The objective of this study is to investigate whether ERBT could improve the 1-yr recurrence rate of NMIBC, as compared with SR.
    METHODS: A multicentre, randomised, phase 3 trial was conducted in Hong Kong. Adults with bladder tumour(s) of ≤ 3cm were enrolled from April 2017 to December 2020, and followed up until 1 yr after surgery. Patients were randomly assigned to receive either ERBT or SR in a 1:1 ratio. The primary outcome was 1-yr recurrence rate. A modified intention-to-treat analysis on patients with histologically confirmed NMIBC was performed. The main secondary outcomes included detrusor muscle sampling rate, operative time, hospital stay, 30-d complications, any residual or upstaging of disease upon second-look transurethral resection, and 1-yr progression rate.
    UNASSIGNED: A total of 350 patients underwent randomisation, and 276 patients were histologically confirmed to have NMIBC. At 1 yr, 31 patients in the ERBT group and 46 in the SR group developed recurrence; the Kaplan-Meier estimate of 1- yr recurrence rates were 29% (95% confidence interval, 18-37) in the ERBT group and 38% (95% confidence interval, 28-46) in the SR group (p = 0.007). Upon a subgroup analysis, patients with 1-3 cm tumour, single tumour, Ta disease, or intermediate-risk NMIBC had a significant benefit from ERBT. None of the patients in the ERBT group and three patients in the SR group developed progression to muscle-invasive bladder cancer; the Kaplan-Meier estimates of 1-yr progression rates were 0% in the ERBT group and 2.6% (95% confidence interval, 0-5.5) in the SR group (p = 0.065). The median operative time was 28 min (interquartile range, 20-45) in the ERBT group and 22 min (interquartile range, 15-30) in the SR group (p < 0.001). All other secondary outcomes were similar in the two groups.
    CONCLUSIONS: In patients with NMIBC of ≤ 3cm, ERBT resulted in a significant reduction in the 1-yr recurrence rate when compared with SR. The study results support ERBT as the first-line surgical treatment for patients with bladder tumours of≤ 3cm.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号